Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.